Search biotalk.co.uk
Biotalk logo

Datamonitor Reports

Browse alphabetically:

Whatever job role and day-to-day information needs, Datamonitor Reports provide a unique mix of market intelligence, insightful analysis and forecasting based on primary quantitative and qualitative research. 50 - 300 pages long each, a single report will provide the full picture on a particular market, issue or trend within the Pharmaceuticals and Healthcare industry.

Report Title
Date
No of Pages
Price
Sales Force Effectiveness Read more…
29-Sep-08
91
$7,600
Schering-Plough Corporation: PharmaVitae Profile Read more…
2-Jul-08
164
$5,700
Sepracor Inc.: PharmaVitae Profile Read more…
27-Oct-08
111
$5,700
Shire plc: PharmaVitae Profile Read more…
10-Nov-08
158
$5,700
Solvay S.A.: PharmaVitae Profile Read more…
20-Oct-08
141
$5,700
Stakeholder Insight: Acute Coronary Syndromes  Fresh look at ACS in Europe, what is the real picture? Read more…
26-Dec-07
164
$30,400
Stakeholder Insight: Asthma - Over-prescribing is common in intermittent and mild forms of asthma Read more…
1-Jul-08
235
$15,200
Stakeholder Insight: Chronic Leukemias - Is there room left for improvement? Read more…
24-Nov-08
362
$15,200
Stakeholder Insight: Diabetes Read more…
26-Dec-07
185
$15,200
Stakeholder Insight: Inflammatory Bowel Disease -  Debate over early aggressive treatment continues Read more…
19-Dec-07
297
$15,200
Stakeholder Insight: Osteoporosis - Generic alendronate further establishes oral bisphosphonates as gold standard Read more…
7-Oct-08
199
$15,200
Stakeholder Insight: Parkinson's Disease - Evidence of neuroprotection essential to progress treatment dynamics Read more…
19-Dec-07
260
$15,200
Stakeholder Insight: Prostate Cancer - Hormone-refractory patients still waiting for treatment breakthroughs Read more…
12-Dec-07
249
$15,200
Stakeholder Insight: Systemic Lupus Erythematosus  Imprecise segmentation complicates treatment algorithms Read more…
18-Nov-08
179
$15,200
Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency Read more…
14-Dec-07
51
$3,800
Stakeholder Opinions: Biologics in Infectious Diseases  Well defined target populations are key to commercial success Read more…
21-Mar-08
123
$3,800
Stakeholder Opinions: Bladder Cancer - New drugs needed to challenge ineffective 20-year old drugs Read more…
12-Nov-08
95
$3,800
Stakeholder Opinions: Bone Metastases - Impending patent expiries may help make or break newer agents Read more…
20-Mar-08
100
$3,800
Stakeholder Opinions: Diabetic Renal Disease Read more…
5-Nov-08
88
$3,800
Stakeholder Opinions: Diagnostics in Neurology - Predictive biomarkers expand drug revenues Read more…
7-Jul-08
152
$3,800
Stakeholder Opinions: Endometriosis - Scientific clarity will unlock market potential Read more…
19-Dec-07
139
$3,800
Stakeholder Opinions: Heart Failure - When drugs do not work Read more…
17-Apr-08
146
$3,800
Stakeholder Opinions: Hepatitis C - Small-molecule antivirals pave the way for triple therapy Read more…
19-Dec-07
142
$3,800
Stakeholder Opinions: Multiple Myeloma - Exploring new targets for multiple drug therapy Read more…
19-Dec-07
107
$3,800
Stakeholder Opinions: Myelodysplastic Syndromes - First approvals spur some interest in a niche market Read more…
19-Dec-07
143
$3,800
Stakeholder Opinions: Non-Hodgkin's Lymphoma - Is there room to emulate Rituxan's success? Read more…
19-Dec-07
174
$3,800
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand Read more…
17-Jun-08
135
$3,800
Stakeholder Opinions: Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of market prospects for biologics expose an opportunity for cell and gene therapies Read more…
2-Jul-08
162
$7,600
Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard Read more…
23-Apr-08
95
$3,800
Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard Read more…
23-Apr-08
95
$3,800
Stakeholder Opinions: Portable Inhaler Devices - Key tools to differentiate brands and survive generic pressure Read more…
2-Apr-08
159
$3,800
Stakeholder Opinions: Restless Legs Syndrome - Novel drugs to prosper as lifecycle management strategies fail Read more…
19-Nov-08
125
$7,600
Stakeholder Opinions: Sepsis - The Critical Care Community Gains Critical Mass Read more…
26-Mar-08
124
$3,800
Stakeholder Opinions: Systemic Lupus Erythematosus - Market set to enter era of biologic therapies Read more…
20-Mar-08
108
$3,800
Stakeholder Opinions: Vaccine adjuvants - uncertainties rule Read more…
12-Sep-08
147
$3,800
Strategic Perspectives: Antidyslipidemics  Current market is not conducive for growth Read more…
22-Oct-08
223
$15,200
eureka room at biotalkeureka
room
We are pleased to introduce global learning institutions enabling knowledge development in the fields of biotechnology and pharma
Read more...
case studies at biotalkproduct showcase
Biotalk: providing you with targeted market research and analysis on the biotechnology industry
Read more...
product showcase at vivo prestobiotalk
events

Biotalk events showcase: providing you with market information and analysis events for the biotechnology industry.
Read more...
partnerships with biotalkpartnerships
with biotalk
Interested in joining the biotalk team? Call us on 07932 424527 or email to find out more about becoming a partner
Read more...
Oakwell Services TA Biotalk
tel: 07932 424527
email:
Registered in England. Reg. No.
site design by CWGD